By Gwendolyn Wu | Published October 26, 2026
In a high-stakes move that underscores the insatiable investor appetite for weight-loss therapeutics, Corxel U.S. has announced its intent to go public through a merger with Amanat Acquisition Corp., a special purpose acquisition company (SPAC). The transaction, confirmed on October 26, 2026, marks a pivotal evolution for the biotechnology firm, which has spent the last two years aggressively repositioning its pipeline to focus exclusively on the lucrative, yet increasingly crowded, GLP-1 and amylin-targeting market.
The move comes backed by a substantial $300 million financing package, positioning the newly minted entity as a significant player capable of taking on the behemoths of the pharmaceutical industry. By spinning off its weight-loss assets into a distinct, publicly traded vehicle, Corxel is signaling to Wall Street that it is ready to transition from a venture-backed research outfit to a commercial-stage competitor.
The Strategic Restructuring: A "Focused" Future
The decision to carve out the obesity-focused assets into a separate entity was not an impulsive one. According to Kevin Xie, Chief Financial Officer of Corxel, the company’s investor base grew increasingly vocal regarding the need for a "dedicated focus."
"Our backers made it clear that they wanted the company to have a more dedicated focus, rather than pursuing two different tracks," Xie noted in an exclusive interview with BioPharma Dive. "Both companies—the public entity and the remaining private parent—now have separate development strategies and financing processes. That is welcome news to our investors, who want clarity on where their capital is being deployed."
This corporate split effectively separates the weight-loss pipeline—led by the promising oral GLP-1 candidate CX11—from the rest of the company’s legacy assets. This allows the public market entity to tell a singular, compelling story to institutional investors: that it is a specialized, pure-play obesity firm operating in a sector currently experiencing a global gold rush.
Chronology of a Transformation: From Dry Eye to Weight Loss
The path to this public debut has been characterized by rapid, surgical asset management. Formerly known as Ji Xing Pharmaceuticals, the company launched in 2019 with a broad, multi-therapeutic mandate. In its early years, the firm gained notice for its pursuit of an OC-01 nasal spray, intended to treat the signs and symptoms of dry eye disease.
However, as the global pharmaceutical landscape shifted toward the metabolic disease "supercycle," the company’s leadership pivoted. The transformation began in earnest in 2024:
- 2024: The company successfully offloaded its dry eye therapy program, shedding non-core assets to focus on its growing metabolic portfolio.
- 2024: Corxel acquired the rights to JX10 from Biogen, a move that bolstered its neurological and metabolic reach.
- 2024: The company licensed CX11 from Vincentage, securing a global asset (excluding Greater China) that would become the cornerstone of its current public offering.
- January 2026: Corxel secured a massive $287 million Series D financing round, providing the runway necessary to complete the current SPAC merger.
- October 2026: Announcement of the definitive merger agreement with Amanat Acquisition Corp.
This aggressive churn of assets reflects a "build-to-buy" philosophy, where the company systematically acquires high-potential, mid-stage clinical assets and aggressively pushes them toward global late-stage trials.
Supporting Data: The Case for CX11
At the heart of the Corxel investment thesis is CX11, an oral small-molecule GLP-1 receptor agonist. The drug is currently being positioned as a "differentiated, next-generation" therapy designed to address the specific pain points of patients who struggle with the limitations of injectable treatments.
Efficacy and Market Positioning
While major players like Eli Lilly and Novo Nordisk have established dominance with their respective GLP-1 offerings, Corxel is targeting a distinct niche. According to Xie, CX11 is being developed not necessarily to replace the heavyweights, but to serve the vast population of individuals classified as overweight—rather than obese—who may be looking for a less invasive, daily oral option to lose 5% to 10% of their body weight.
According to data from the National Institutes of Health (NIH), approximately 31% of U.S. adults fall into this "overweight" category. By targeting this demographic with an oral pill, Corxel hopes to capture a segment of the market that may be hesitant to commit to chronic, long-term injectable therapy.
Clinical Milestones
The drug has already shown promise. In May 2026, Corxel reported positive top-line results from a pivotal Phase 3 trial of the drug (known as VCT220 in the Chinese market) conducted by its partner, Vincentage Pharma. The data demonstrated a competitive profile, suggesting that the drug is both effective and well-tolerated.
Currently, the company is conducting a Phase 1b trial utilizing higher doses of CX11. The goal of this trial is to define the "efficacy upside" of the drug, effectively testing whether higher concentrations can yield more significant weight loss without compromising the safety profile. Additional data from this study is anticipated in the first half of 2027, just as the company prepares for its international Phase 3 launch.
Official Responses and Investor Sentiment
The market reaction to the announcement has been one of cautious optimism. For institutional investors, the SPAC merger provides an opportunity to enter the obesity space at a valuation that may be more favorable than the heavily inflated prices of established industry leaders.
Kevin Xie emphasized that the move to public markets provides the "capital velocity" required to scale global clinical trials. "The drug has demonstrated a really competitive profile," Xie said, noting that the $300 million in new financing will be primarily funneled into the upcoming international Phase 3 program.
The strategy is clearly to hit the ground running. By initiating global Phase 3 trials as early as the first quarter of 2027, Corxel intends to compress the time-to-market, aiming to reach regulatory filing windows before the market for oral GLP-1s becomes fully saturated by generic or biosimilar competition.
Implications for the Obesity Drug Market
The entry of Corxel into the public markets highlights several broader trends currently shaping the pharmaceutical industry:
- The Rise of the Pure-Play Biotech: Investors are increasingly moving away from conglomerates and toward companies with hyper-focused pipelines. By shedding its dry-eye and legacy portfolios, Corxel has successfully transformed itself into a "thematic" investment that aligns with the current obsession with metabolic health.
- The Oral Revolution: The "holy grail" of the obesity market remains the transition from injectables to oral medication. While CX11 is playing catch-up to established players, its potential for oral administration makes it a high-value asset for potential acquisition or partnership by larger pharmaceutical firms.
- SPACs as a Viable Path: Despite a cooling in the broader SPAC market over the last few years, this deal proves that for high-growth, high-need sectors like metabolic disease, the SPAC vehicle remains a fast-track route to liquidity. It allows a company to bypass the protracted traditional IPO process and reach the public markets with a secured balance sheet.
Future Outlook
As Corxel moves into the public arena, the pressure to deliver on its clinical milestones will intensify. The upcoming data from its Phase 1b trials and the subsequent initiation of the global Phase 3 study will serve as the primary catalysts for the stock.
Should the data continue to mirror the positive results seen in the Chinese trials, Corxel could find itself in a position of significant leverage. However, the company must navigate a landscape fraught with regulatory scrutiny, aggressive competition from "Big Pharma," and the inherent risks of late-stage clinical development.
For now, the company has managed to check all the right boxes: a focused strategy, a robust financing war chest, and a clinical asset with a clear, defined path to the consumer. Whether Corxel can maintain this momentum in the public eye remains the defining question for the year ahead. Investors, researchers, and patients alike will be watching closely as the company prepares for its first earnings call as a public entity, marking the next chapter in the ongoing battle against the global obesity epidemic.
About the Author
